43 related articles for article (PubMed ID: 822769)
1. [An acellular vaccine from "Pseudomonas aeruginosa." I. Preparation and activity (author's transl)].
Berche P; Véron M; Tinelli R
Ann Microbiol (Paris); 1976; 127A(2):247-59. PubMed ID: 822769
[TBL] [Abstract][Full Text] [Related]
2. [An acellular vaccine from Pseudomonas aeruginosa. II. -- Estimate of immuneserum protective effect by measure of bacterial clearance (author's transl)].
Daoulas-Le Bourdelles F; Berche P; Véron M
Ann Microbiol (Paris); 1977 Jul; 128B(1):61-71. PubMed ID: 410340
[TBL] [Abstract][Full Text] [Related]
3. Mouse-protection experience with monovalent Pseudomonas aeruginosa vaccine.
Sourek J; Výmola F; Zelenková L
Zentralbl Bakteriol A; 1980 Mar; 246(3):353-62. PubMed ID: 6775443
[TBL] [Abstract][Full Text] [Related]
4. Active and passive mouse-protecting capacity of Pseudomonas aeruginosa protein vaccines.
Joó I; Stanislavsky ES; Zhvanetskaya MI; Mashilova GM; Gladus MA
Acta Microbiol Acad Sci Hung; 1982; 29(4):267-75. PubMed ID: 6821018
[TBL] [Abstract][Full Text] [Related]
5. Investigations on the efficacy of monovalent Pseudomonas aeruginosa vaccine for oral administration in Pseudomonas aeruginosa experimental infection.
Meitert E; Sima F; Savulian C; Petrovici M; Chersulick E; Costache G
Arch Roum Pathol Exp Microbiol; 1989; 48(3):237-51. PubMed ID: 2519634
[TBL] [Abstract][Full Text] [Related]
6. A new polyvalent pseudomonas vaccine.
Merle P; Robbel L; Hungerer KD
Behring Inst Mitt; 1984 Nov; (76):113-20. PubMed ID: 6441560
[TBL] [Abstract][Full Text] [Related]
7. General pharmacology of a Pseudomonas vaccine prepared from outer-membrane fractions of Pseudomonas aeruginosa.
Park WJ; Kim YH; Jeong SM; Park KH; Kim HS; Kim YS; Hahm KS; Munt PL; Algate DR
Arzneimittelforschung; 1996 Oct; 46(10):1001-6. PubMed ID: 8931896
[TBL] [Abstract][Full Text] [Related]
8. Development of an anti-adhesive vaccine for Pseudomonas aeruginosa targeting the C-terminal region of the pilin structural protein.
Sheth HB; Glasier LM; Ellert NW; Cachia P; Kohn W; Lee KK; Paranchych W; Hodges RS; Irvin RT
Biomed Pept Proteins Nucleic Acids; 1995; 1(3):141-8. PubMed ID: 9346845
[TBL] [Abstract][Full Text] [Related]
9. Pseudomonas aeruginosa. II. Experimental acellular vaccine of an endotoxin and anatoxin type.
Bĕlohlávek S; Pavlík V; Rencová J; Stránský V; Nováková L; Sourek J; Výmola F
J Hyg Epidemiol Microbiol Immunol; 1987; 31(3):343-52. PubMed ID: 3119704
[TBL] [Abstract][Full Text] [Related]
10. Prophylactic and therapeutic efficacy of immunoglobulin G antibodies to Pseudomonas aeruginosa lipopolysaccharide against murine experimental corneal infection.
Preston MJ; Gerçeker AA; Koles NL; Pollack M; Pier GB
Invest Ophthalmol Vis Sci; 1997 Jun; 38(7):1418-25. PubMed ID: 9191605
[TBL] [Abstract][Full Text] [Related]
11. Heat-killed Pseudomonas aeruginosa as a systemic adjuvant in cancer immunotherapy.
Mathé G; Florentin I; Bruley-Rosset M; Hayat M; Bourut C
Biomedicine; 1977 Dec; 27(9-10):368-73. PubMed ID: 414800
[TBL] [Abstract][Full Text] [Related]
12. Effects of somatic component of Pseudomonas aeruginosa on protective immunity in experimental mouse burn infection.
Okada K; Kawaharajo K; Kasai T; Homma JY
Jpn J Exp Med; 1980 Feb; 50(1):53-61. PubMed ID: 6770131
[TBL] [Abstract][Full Text] [Related]
13. [Results of using polyvalent Pseudomonas aeruginosa vaccine in children with burns by various medical centers].
Bbukowska D; Serafińska D; Rudowski W; Hoffman S; Olański W; Gardzińska E; Popiel D; Jedrzejczak G; Czarnecka I
Pol Tyg Lek; 1989 Oct 23-Nov 6; 44(43-45):924-7. PubMed ID: 2518666
[TBL] [Abstract][Full Text] [Related]
14. Effect of common protective antigen vaccination to protect mink from challenge exposure with Pseudomonas aeruginosa.
Shimizu T; Homma JY; Abe C; Tanamoto T; Aoyama Y; Yanagawa R; Fujimoto Y; Noda H; Takashima I; Honda E; Minamide S
Am J Vet Res; 1976 Dec; 37(12):1441-4. PubMed ID: 826199
[TBL] [Abstract][Full Text] [Related]
15. [Toxicological assessment on safety of water and 70% ethanolic extracts of nearly ripe fruit of Evodia rutaecarpa].
Yang XW
Zhongguo Zhong Yao Za Zhi; 2008 Jun; 33(11):1317-21. PubMed ID: 18831217
[TBL] [Abstract][Full Text] [Related]
16. Multi-valent human monoclonal antibody preparation against Pseudomonas aeruginosa derived from transgenic mice containing human immunoglobulin loci is protective against fatal pseudomonas sepsis caused by multiple serotypes.
Lai Z; Kimmel R; Petersen S; Thomas S; Pier G; Bezabeh B; Luo R; Schreiber JR
Vaccine; 2005 May; 23(25):3264-71. PubMed ID: 15837231
[TBL] [Abstract][Full Text] [Related]
17. [Ticarcillin activity in immunodepressed mice infected with "Pseudomonas aeruginosa" (author's transl)].
Fauchère JL; Simonet M; de Meirleire F; Véron M
Ann Microbiol (Paris); 1981; 132B(2):215-24. PubMed ID: 6798910
[TBL] [Abstract][Full Text] [Related]
18. Protection against pulmonary infection with Pseudomonas aeruginosa following immunization with P. aeruginosa-pulsed dendritic cells.
Worgall S; Kikuchi T; Singh R; Martushova K; Lande L; Crystal RG
Infect Immun; 2001 Jul; 69(7):4521-7. PubMed ID: 11401995
[TBL] [Abstract][Full Text] [Related]
19. [Morphological study of the organs and tissues of mice infected after a burn with a Pseudomonas aeruginosa strain and treated with a Pseudomonas aeruginosa polyvalent corpuscular vaccine and tobramycin].
Moroz AF; Kharitonova AM; Chanturiia TsK
Antibiotiki; 1983 May; 28(5):341-5. PubMed ID: 6410985
[TBL] [Abstract][Full Text] [Related]
20. Pseudomonas aeruginosa mastitis outbreaks in sheep and goat flocks: antibody production and vaccination in a mouse model.
Leitner G; Krifucks O
Vet Immunol Immunopathol; 2007 Oct; 119(3-4):198-203. PubMed ID: 17644188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
